Trial Profile
An Open-Label Multicenter Study of the Continued Safety of Istradefylline (KW-6002) In Subjects With Parkinson's Disease Who Have Recently Completed One Year of Treatment With Istradefylline. [EXTENSION of 700013885]
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 24 Jul 2023
Price :
$35
*
At a glance
- Drugs Istradefylline (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Kyowa Kirin Pharmaceutical Development
- 06 Aug 2013 New trial record